Journal issues > Issue 3, May 2022 > Refractory pyrexia caused by BRAF and MEK inhibitors: Colchicine as salvage

Refractory pyrexia caused by BRAF and MEK inhibitors: Colchicine as salvage

By: M. Saerens MD, I. Hilderson MD, L. Brochez MD, PhD, A. Hoorens MD, PhD, C. Jacobs MD

SUMMARY

Pyrexia is a frequent complication of the treatment with BRAF and MEK inhibitors. Its management includes a full infectious workup, initiation of paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), dose interruption and steroids. In rare cases, pyrexia is refractory to steroids. Pathogenesis of pyrexia shows similarities with familial Mediterranean fever, a disease that usually responds well to colchicine. This study presents a case of refractory pyrexia due to BRAF and MEK inhibitors in metastatic melanoma, successfully treated with colchicine, which paved the path for a significant treatment response.

(BELG J MED ONCOL 2022;16(3):128–32)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top